Aytu BioPharma (AYTU) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free AYTU Stock Alerts $2.94 -0.02 (-0.68%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | finance.yahoo.comQ3 2024 Aytu Biopharma Inc Earnings CallMay 16, 2024 | finance.yahoo.comAytu BioPharma Inc (AYTU) Q3 2024 Earnings Call Transcript Highlights: Strategic Gains Amidst ...May 15, 2024 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial ResultsMay 15, 2024 | markets.businessinsider.comHere's what Wall Street expects from Aytu BioPharma's earnings reportApril 17, 2024 | morningstar.comAytu BioPharma Inc 0A8MApril 2, 2024 | msn.comRedHill Biopharma looks to raise $1.25M in a direct offering of securitiesMarch 24, 2024 | morningstar.comAytu BioPharma Inc AYTUMarch 19, 2024 | seekingalpha.comSeelos drops as lead drug fails in ALS trialMarch 18, 2024 | seekingalpha.comSeelos Therapeutics files for 3.4M shares secondary offeringFebruary 25, 2024 | msn.comAytu BioPharma (AYTU) Price Target Increased by 60.00% to 8.16February 16, 2024 | finance.yahoo.comAytu BioPharma Second Quarter 2024 Earnings: Beats ExpectationsFebruary 16, 2024 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call TranscriptFebruary 15, 2024 | finance.yahoo.comQ2 2024 Aytu Biopharma Inc Earnings CallFebruary 14, 2024 | finance.yahoo.comAytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second QuarterFebruary 13, 2024 | benzinga.comEarnings Preview: Aytu BioPharmaFebruary 7, 2024 | finance.yahoo.comAytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024January 23, 2024 | finance.yahoo.comAytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024January 16, 2024 | finance.yahoo.comWhen Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Become Profitable?December 18, 2023 | benzinga.comAytu BioPharma Stock (NASDAQ:AYTU) Dividends: History, Yield and DatesNovember 30, 2023 | finance.yahoo.comAytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023November 15, 2023 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call TranscriptNovember 14, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2024 First Quarter Financial ResultsNovember 14, 2023 | finance.yahoo.comAytu BioPharma Reports Fiscal 2024 First Quarter Financial ResultsNovember 13, 2023 | markets.businessinsider.comAytu BioPharma earnings: here's what to expectNovember 8, 2023 | finance.yahoo.comAytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive YearNovember 7, 2023 | finance.yahoo.comAytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023October 28, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval SupplementOctober 28, 2023 | markets.businessinsider.comAytu BioPharma: Strategic Manufacturing Transition and Financial Growth Bolster Buy RatingOctober 26, 2023 | finance.yahoo.comAytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval SupplementOctober 9, 2023 | finance.yahoo.comAytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023September 28, 2023 | finance.yahoo.comThere's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted RevenuesSeptember 28, 2023 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call TranscriptSeptember 27, 2023 | finance.yahoo.comAytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023September 26, 2023 | benzinga.comEarnings Outlook For Aytu BioPharmaSeptember 26, 2023 | markets.businessinsider.comAytu BioPharma earnings: here's what Wall Street expectsSeptember 22, 2023 | finance.yahoo.comAytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023September 13, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma to Present at LD Micro Main Event XVI ConferenceSeptember 13, 2023 | finance.yahoo.comAytu BioPharma to Present at LD Micro Main Event XVI ConferenceAugust 9, 2023 | msn.comMaxim Group Initiates Coverage of Aytu BioPharma (AYTU) with Buy RecommendationAugust 9, 2023 | finance.yahoo.comLoss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Expected To Breakeven In The Medium-TermJuly 31, 2023 | finance.yahoo.comAytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian AuthorityJuly 6, 2023 | msn.comAytu BioPharma (AYTU) Price Target Increased by 71.43% to 122.40June 14, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu to Participate in the Maxim Group Virtual Healthcare ConferenceJune 13, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-MarketJune 13, 2023 | finance.yahoo.comAytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-MarketJune 9, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New DirectorMay 31, 2023 | msn.comHC Wainwright & Co. Reiterates Aytu BioPharma (AYTU) Buy RecommendationMay 16, 2023 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2023 Earnings Call TranscriptMay 11, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comAytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Pioneer Says: “The last crypto bull market has begun.” (Ad)Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble. Click here if you’d like to learn more about these five cryptos… AYTU Media Mentions By Week AYTU Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AYTU News Sentiment▼0.720.42▲Average Medical News Sentiment AYTU News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AYTU Articles This Week▼50▲AYTU Articles Average Week Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Galecto News Sol-Gel Technologies News Indaptus Therapeutics News VBI Vaccines News Cocrystal Pharma News GlycoMimetics News Minerva Neurosciences News Talphera News KALA BIO News NeuroBo Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AYTU) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.